AstraZeneca, breast cancer and US FDA
FDA Approves New ADC for HR+, HER2- Breast Cancer
The US Food and Drug Administration (FDA) has approved datopotamab deruxtecan for the treatment of certain patients with unresectable or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer.
AstraZeneca’s Datroway approved in U.S. for HER2-negative breast cancer patients
DXd, has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.
51mon MSN
2024 was a year unlike any other for the British royal family, as Fergie, King Charles and Kate Middleton all announced that ...
It’s a sobering statistic: 1 in 8 women in the United States will be diagnosed with breast cancer during her lifetime.1 ...
Morgan Pressel's 18th annual Morgan & Friends event raised a record $1,022,000 to support the fight against breast cancer.
Danielle Fishel is sharing an update about her health, saying she has completed “active cancer treatment” following her ...
The increase in breast cancer rates among younger patients is occurring as the incidence of other early-onset cancers — ...
If you have breast cancer, you will have changes in your breast. These may be lumps or changes in the size or color of your breast, or changes in the appearance of your nipples. Breast cancer ...
As cancer treatment costs have increased, identifying and treating early-stage cancer sooner reduces expenses and improves ...
Questions about sex and intimacy often go unanswered for people with cancer. It's a glaring problem, especially for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback